BIOFLOR Powder for oral suspension Ref.[28146] Active ingredients: Saccharomyces boulardii

Source: Υπουργείο Υγείας (CY)  Revision Year: 2021 

5.1. Pharmacodynamic properties

ANTI-DIARRHOEA
Replacement flora

Pharmacotherapeutic group: A, digestive system and metabolism
ATC code: A07FA02

Saccharomyces boulardii CNCM I-745 is an intestinal flora replacement which acts as antidiarrheal microorganisms in the digestive tract.

Pharmacodynamics of Saccharomyces boulardii CNCM I-745, live probiotic cultures, have been established on various models by in vitro and in vivo, animal, and human studies which demonstrated it has:

  • anti-inflammatory (enterohemorrhagic E. Coli) effect,
  • anti-microbial (enterohemorrhagic E. Coli; C. difficile; S. typhimurium; Yersinia enterolitica; C. albicans; C. krusei; C. pseudotropicalis) effect,
  • enzymatic (disaccharidases; leucine aminopeptidase; spermine; spermidine) effect,
  • metabolic effect,
  • anti-toxin (C. diff. toxin A; cholera toxin) effect,
  • and immuno-enhancing (secretory-IgA and immunoglobulins) effect

which are beneficial when Saccharomyces boulardii CNCM I-745 is used to treat diarrhea of various origins (infectious viral, bacterial or not) in humans.

5.2. Pharmacokinetic properties

Analysis of the fecal elimination kinetics of living S. boulardii CNCM I-745 cells during repeated dosing with 1 g/day of Saccharomyces boulardii CNCM I-745 in healthy adult volunteers showed that steady state is reached by the third day of administration. S. boulardii CNCM I-745 quickly disappears from stools 2 to 5 days after treatment is stopped. Fecal recovery rates follow a linear dose/recovery relation. The recovery rate is more than two-fold higher when subjects take simultaneously an antibiotic (ampicillin) active on the dominant anaerobic flora of the colon. In a clinical trial of patients with multi-recurrent C. difficile infection treated with S. boulardii CNCM I-745 at the dose of 1 g/day, fecal levels of viable yeast cells in patients who did not have subsequent relapses was on average greater than that seen in patients who had a relapse.

5.3. Preclinical safety data

LD50 is much higher than the maximal administered dose of 3,000 mg/kg – repeated dose toxicity has been tested for 6 months in rats and 6 weeks in rabbits without any damage for animals.

An Ames test has been performed and no mutagenic effect has been observed. There is no available data on reproduction.

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.